lung cancer

[Scientific Reports] Secretion analysis revealed that cancer cells vary in their secretion level, with some cell lines having relatively low secretion rates.

[Cell Death & Disease] Researchers explored the downstream mechanism of Jumonji domain containing protein 2C (JMJD2C) in NSCLC from the long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1/microRNA-503-5p/septin 2 axis.

[Amgen, Inc.] Amgen announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer that has progressed after systemic anticancer therapy.

[Ludwing Cancer Research] Cancer Research UK, Vaccitech plc and the Ludwig Institute for Cancer Research, announced the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer.

[Molecular Biology Reports] Researchers demonstrated that As2O3 had a remarkable inhibitory effect on tumor initiating cells of small cell lung cancer both in vitro and in vivo, and the mechanism might have involved the down-regulation of Notch pathway

[Laboratory Investigation] Silencing procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD3) promoted the cleavage ofprotein kinase C δ (PKCδ) in a caspase-dependent manner to generate a catalytically active fragment cleaved PKCδ, enhanced phosphorylation levels of CDK1, and LIMD1 but suppressed nuclear translocation of YAP1.